Study tests treatments for early kidney transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This is a study of people who have a specific type of early rejection after a kidney transplant (“acute antibody-mediated rejection”). The study aims to understand what treatments work and why, to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign informed consent before any study-specific steps
- This study is for participants already enrolled in the TAR:GET-1 study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This study looks at how the body’s immune system responds when a kidney transplant shows signs of rejection, using a planned kidney biopsy. It may help doctors better understand what drives rejection and how to improve care in the future.
This study looks at how well a new blood test works to monitor kidney health after a transplant. It might help doctors catch problems early without needing a biopsy.
Hear when a new Transplant; Complication, Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.